Welcome to our dedicated page for Astria Therapeutics SEC filings (Ticker: ATXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Astria Therapeutics, Inc. (ATXS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq‑listed biopharmaceutical issuer. Astria’s filings, including Forms 8‑K, 10‑K, and 10‑Q when available, document key information about its clinical‑stage programs in hereditary angioedema and atopic dermatitis, as well as its material agreements and corporate transactions.
Recent Form 8‑K filings illustrate how Astria uses SEC reports to communicate significant events. One 8‑K describes an Agreement and Plan of Merger with BioCryst Pharmaceuticals, Inc., under which a BioCryst subsidiary will merge with and into Astria, with Astria surviving as a wholly owned subsidiary if closing conditions are met. The filing outlines the cash and stock consideration, treatment of common stock, preferred stock, options, and warrants, and notes that Astria common stock is expected to be delisted from Nasdaq and deregistered under the Exchange Act if the merger is consummated.
Another 8‑K details a license agreement with Kaken Pharmaceutical Co., Ltd., granting Kaken exclusive rights to develop, package, and commercialize navenibart in Japan for prevention of hereditary angioedema attacks, including financial terms such as an upfront payment, potential milestones, and tiered royalties, as well as Kaken’s obligations to support Phase 3 development and handle regulatory submissions in Japan. Additional 8‑K filings cover quarterly financial results and other corporate updates.
On Stock Titan, these SEC filings are paired with AI‑powered summaries that explain the core points of lengthy documents, helping readers quickly understand merger terms, licensing economics, clinical development commitments, and capital considerations. Real‑time updates from EDGAR ensure new Astria filings, including future 10‑K annual reports, 10‑Q quarterly reports, and any Form 4 insider transaction reports, are surfaced promptly, while AI‑generated highlights make dense regulatory language more accessible for investors researching ATXS.
Astria Therapeutics (ATXS) signed an exclusive license with Kaken Pharmaceutical for Japanese rights to navenibart, its long-acting plasma-kallikrein mAb for hereditary angioedema (HAE). Kaken will lead development, regulatory submissions and commercialization in Japan and will support Astria’s ALPHA-ORBIT Phase 3 trial.
Financial terms: Astria receives a $16 million upfront, up to $16 million in commercial/sales milestones, and tiered royalties ranging from the mid-teens to 30 % of net sales. Royalties run until the later of patent or regulatory exclusivity expiry, or 10 years after first sale.
The upfront plus partial Phase 3 cost reimbursements extend Astria’s cash runway into 2028, covering completion of the Phase 3 program for navenibart and the Phase 1a study of STAR-0310. Management cautions that substantial additional funding will still be needed to finish development and commercialization.
The agreement includes a joint steering committee, Kaken’s right of first negotiation for non-HAE indications, and termination rights for breach, insolvency, safety issues or at Kaken’s convenience (90-day notice).